JNJ
Earnings Whisper ®
N/A
4th Quarter December 2025
Consensus: $2.53
Revenue: $24.06 Bil
Share
Watch
Guidance announcement made Tuesday, October 14, 2025
Latest EPS
Tuesday, October 14, 2025
What do you expect when JNJ reports earnings?
Where is JNJ's stock price going from here?
Analysts
Pivots
Resistance
$195.91
$194.76
$193.99
Support
$192.06
$190.91
$190.14
Description
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.